Guillain-Barre Syndrome – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Guillain-Barre Syndrome – Pipeline Review, H1 2017’, provides an overview of the Guillain-Barre Syndrome pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Guillain-Barre Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Guillain-Barre Syndrome and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Guillain-Barre Syndrome

The report reviews pipeline therapeutics for Guillain-Barre Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Guillain-Barre Syndrome therapeutics and enlists all their major and minor projects

The report assesses Guillain-Barre Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Guillain-Barre Syndrome

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Guillain-Barre Syndrome

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Guillain-Barre Syndrome pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Akari Therapeutics Plc

Annexon Inc

CuraVac Inc

Hansa Medical AB

Regenesance BV

Vitality Biopharma Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Guillain-Barre Syndrome - Overview

Guillain-Barre Syndrome - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Guillain-Barre Syndrome - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Guillain-Barre Syndrome - Companies Involved in Therapeutics Development

Akari Therapeutics Plc

Annexon Inc

CuraVac Inc

Hansa Medical AB

Regenesance BV

Vitality Biopharma Inc

Guillain-Barre Syndrome - Drug Profiles

ANX-005 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Coversin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

immune globulin (human) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptide for Cholera and Guillain-Barre Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Enzyme to Inhibit Immunoglobulin G for Kidney Transplantation, Central Nervous System and Autoimmune Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit C6 for Guillain-Barre Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize CB1 and CB2 for Central Nervous System Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Guillain-Barre Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Guillain-Barre Syndrome - Dormant Projects

Guillain-Barre Syndrome - Product Development Milestones

Featured News & Press Releases

Feb 16, 2017: Novel pre-clinical in vivo data demonstrate the treatment potential of IdeS in Guillain-Barre syndrome

May 23, 2016: Akari Therapeutics Receives Positive Opinion for Orphan Drug Designation for Coversin in the European Union for Treatment of Guillain-Barre Syndrome

May 12, 2016: Akari Therapeutics Announces Receipt of Orphan Drug Designation for Coversin from the U.S. FDA for Treatment of Guillain-Barre Syndrome

Jan 29, 2016: Akari Therapeutics Receives Approval From the UK Medicines & Healthcare Products Regulatory Agency for Phase IB Multiple Ascending Dose Trial

Jan 05, 2016: Akari Therapeutics Announces Additional Data from Non-Human Primate Safety Study Demonstrating Equivalent Coversin Efficacy in Both Elisa CH50 and Hemolytic SRBC Assays

Dec 07, 2015: Akari Therapeutics Announces Update From Non-Human Primate Safety Study at International PNH Interest Group 10th Annual Scientific Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Guillain-Barre Syndrome, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Guillain-Barre Syndrome – Pipeline by Akari Therapeutics Plc, H1 2017

Guillain-Barre Syndrome – Pipeline by Annexon Inc, H1 2017

Guillain-Barre Syndrome – Pipeline by CuraVac Inc, H1 2017

Guillain-Barre Syndrome – Pipeline by Hansa Medical AB, H1 2017

Guillain-Barre Syndrome – Pipeline by Regenesance BV, H1 2017

Guillain-Barre Syndrome – Pipeline by Vitality Biopharma Inc, H1 2017

Guillain-Barre Syndrome – Dormant Projects, H1 2017

List of Figures

List of Figures

Number of Products under Development for Guillain-Barre Syndrome, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports